HIV in the female genital tract: Viral shedding and mucosal immunity

Clinical Obstetrics and Gynecology

Volumn 44, Issue 2, 2001, Pages 144-153

  Al Harthi, Lena ^a   Landay, Alan ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE; DISEASE TRANSMISSION; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MENSTRUAL CYCLE; MUCOSAL IMMUNITY; REVIEW; VIRUS SHEDDING;

FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY; MENSTRUAL CYCLE; MUCOUS MEMBRANE; VIRUS SHEDDING;

EID: 0035033151     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200106000-00005     Document Type: Review

References (77)

1. AIDS in women in the United States. Recent trends
2. Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus
3. Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS
4. Isolation patterns of the human immunodeficiency virus from cervical secretions during the menstrual cycle of women at risk for the acquired immunodeficiency syndrome
5. Detection of HIV p17 antigen in lymphocytes but not epithelial cells from cervicovaginal secretions of women seropositive for HIV: Implications for heterosexual transmission of the virus
6. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women
7. Productive infection of a cervical epithelial cell line with human immunodeficiency virus: Implications for sexual transmission
8. Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus
9. An assay for HIV infection of cultured human cervix-derived cells
10. Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by sis in a process impaired by mucosal immunoglobulins
11. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances transinfection of T cells
12. Prevalence and correlates of HIV type 1 shedding in the female genital tract
13. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases
14. Histopathology of endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, Trichomonas vaginalis, and Neisseria gonorrhoeae
15. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
16. Effect of interleukin-1 on the augmentation of human immunodeficiency virus gene expression
17. The effect of cytokines and pharmacologic agents on chronic HIV infection
18. Tumor necrosis factor alpha and interleukin-1 beta induce specific subunits of NFKB to bind the HIV-1 enhancer: Characterisation of transcription factors controlling human immunodeficiency virus type 1 gene expression in neural cells
19. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand
20. Bacterial vaginosis- associated microflora isolated from the female genital tract activates HIV-1 expression
21. Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat
22. Progesterone implants enhance SIV vaginal transmission and early virus load
23. Estrogen protects against vaginal transmission of SIV
24. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy
25. Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro
26. Cytokines in the cervical vaginal environment
27. Human vaginal leukocytes and the effects of vaginal fluid on lymphocyte and macrophage defense functions
28. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women
29. Evaluation of immunologic markers in cervico-vaginal fluid of HIV-infected and uninfected women: Implications for the immunologic response to HIV in the female genital tract
30. Team ftWS. Effect of menstrual cycle on human immunodeficiency virus type 1 levels in the peripheral blood and genital tract
31. Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle
32. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: Implications for applying measurements to individual patients
33. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine
34. Effect of HIV infection on menstrual cycle length
35. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women
36. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood
37. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission
38. The mucosal immune system in the human female reproductive tract: Potential insights into the heterosexual transmission of HIV
39. Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women
40. Cervico-vaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection
41. Local synthesis of IgG antibodies to HIV within the female and male genital tracts during asymptomatic and preAIDS stages of HIV infection
42. The distribution of immunocompetent cells in the genital tract of HIV-positive women
43. Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: A comparison between intravenously and genitally inoculated rhesus macaques
44. Immunology of the vagina
45. Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women: Correlation with other immune mediators
46. Human vaginal leukocytes and the effect of vaginal fluid on lymphocyte and macrophage defense functions
47. CD3+ CD8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause
48. Mucosal immunity in the human female reproductive tract: Cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women
49. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women
50. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
51. Quantification of HIV-1-speciifc T-cell responses at the mucosal cervicovaginal surface
52. Women, HIV, and mucosal immunity
53. Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women
54. Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection
55. Biologic features of HIV-2. An update
56. Reduced rate of disease development after HIV-2 infection as compared to HIV-1
57. Protection from HIV-1 infection by HIV-2
58. Molecular inhibition of HIV type 1 by HIV type 2: Effectiveness in peripheral blood mononuclear cells
59. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
60. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
61. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers
62. Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission
63. Upregulation of beta-chemokines and downmodulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in nonhuman primates
64. A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer
65. A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1-infected and uninfected women
66. Association of indicators of bacterial vaginosis with a female genital tract factor that induces expression of HIV-1
67. Host factors and the pathogenesis of HIV-induced disease
68. The impact of the ovulatory cycle on cytokine production: Evaluation of systemic, cervicovaginal, and salivary compartments
69. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA
70. Human immunodeficiency virus type 1 RNA shedding in the female genital tract
71. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions
72. HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1
73. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women
74. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals
75. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
76. A rational basis for mucosal vaccination against HIV infection
77. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques